Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2024-02-07 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于首次回购公司股份暨回购股份比例达到1%的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase and the repurchase reaching 1% of total shares. It details the number of shares repurchased, prices, total amount, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but is a disclosure of a share buyback event. This fits the definition of a Transaction in Own Shares (POS) filing, which reports the company buying back its own shares.
2024-02-07 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a share repurchase plan by the company 西藏易明西雅医药科技股份有限公司. It details the board's approval of the share buyback plan, the intended funding amount, price limits, and the timeline for the repurchase. It also states that as of January 31, 2024, no shares have been repurchased yet and that the company will continue to disclose updates monthly during the repurchase period. The document is not a full financial report but a regulatory announcement about the company's share repurchase activity. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares.
2024-02-02 Chinese
2023年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩预告" which translates to "2023 Annual Performance Forecast." It provides preliminary estimated financial results for the full year 2023, including net profit and earnings per share, and discusses reasons for performance changes such as goodwill impairment and business impacts. It explicitly states that the data is preliminary, unaudited, and that detailed financial data will be disclosed in the full annual report later. The document is short (1518 characters) and serves as a performance forecast announcement rather than a full annual report or audited financial statement. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only, not the full detailed report. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-01-29 Chinese
关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the release of a portion of pledged shares held by a controlling shareholder. It details the number of shares released from pledge, the shareholder involved, and the status of pledged shares. There are no financial statements, earnings data, or management discussion. The document is short (1276 characters) and serves as a disclosure of a share pledge release event. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share pledge status, not a financial report or capital change announcement like a share issue or buyback.
2024-01-15 Chinese
关于使用自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using its own funds for cash management, specifically investing in financial products. It details the amounts, investment products, risk assessments, and compliance with regulatory requirements. The document is relatively short (2954 characters) and does not contain financial statements or comprehensive financial data. It is an update on financing activities related to cash management and investment of idle funds, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2024-01-15 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a share repurchase program by the company 西藏易明西雅医药科技股份有限公司. It details the board's approval of the share buyback plan, the intended use of funds, the price limits, and the reporting obligations under Shenzhen Stock Exchange regulations. It specifically states the company has not yet repurchased shares as of December 31, 2023, and will continue to disclose progress monthly. This is a typical format for a Transaction in Own Shares (POS) announcement, reporting on share buyback activities. The document length is short and focused solely on the share repurchase progress, not a full financial report or other type of filing.
2024-01-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.